Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse
- 729 Downloads
The aim of the present paper is to study which prescription pain medications are most commonly dispensed to people with chronic headache (CH), particularly those with medication-overuse headache (MOH).
This cross-sectional study analysed prescription pain medications dispensed within 1 year to 68,518 respondents of a national health survey. Participants with headache ≥15 days per month for 3 months were classified as having CH. Those with CH and over-the-counter analgesic use ≥15 days per month or purchase of ≥20 or ≥30 defined daily doses (DDDs) of prescription pain medication per month (depending on the drug) were classified as having MOH. Associations between CH and other chronic pain conditions were analysed by logistic regression.
Among those with CH (adjusted prevalence 3.3 %, CI 3.2–3.5 %), pain medications most commonly dispensed were paracetamol, tramadol, ibuprofen and codeine. CH was associated with osteoarthritis, back pain, and rheumatoid arthritis. Among those with MOH, 32.4 % were dispensed an opioid at least once within 1 year. Only 5.1 % of people with CH were dispensed triptans.
High prevalence of opioid use among people with CH may be due to inappropriate headache treatment or development of MOH among those treated for other pain conditions. While there were cases of triptan overuse, triptans remain underutilized among those with CH, suggesting that migraine may be under-recognized and inappropriately treated, leading to overuse of other medications. Education of physicians on appropriate headache management is essential for MOH prevention. There is a need to increase universal awareness about MOH as an adverse effect of long-term analgesic use.
KeywordsPharmacoepidemiology Analgesics Triptans Opioids Chronic headache Secondary headache disorders Medication-overuse headache
The authors thank the Research Centre for Prevention and Health, especially data manager Carsten Agger, and the team responsible for the Danish National Health Survey; Inger Helt Poulsen for facilitating use of data from Region Zealand; and Statistics Denmark for management of the raw data. Furthermore, we thank everyone who responded to the surveys.
This study did not receive corporate sponsorship. The Region Zealand Health Profile 2010 and The Capital Region Health Profile 2010 were funded by The Region Zealand and The Capital Region of Denmark. MW received research grants from IMK Almene Fond and the patient organization Migræne og Hovedpineforeningen in connection with this study.
Conflict of interest statement
MW received travel grants from Pfizer, Lundbeck Fund, and Allergan to attend international conferences. RJ has given lectures for Pfizer, Berlin-Chemie, Allergan, Merck, and Autonomic Technologies; is a member of the advisory boards of Autonomic Technologies, Medotech, and Neurocore; and is co-director of Lifting The Burden and EHMTIC. EHH and CG declare that they have no conflict of interest.
MLW preformed the drafting and revising the manuscript, study concept, statistical analysis, and interpretation of data; EHH for revising the manuscript, study concept, interpretation of data, and study supervision; CG for revising the manuscript, study design, acquisition and interpretation of data, obtaining funding, study supervision, and coordination; and RHJ for revising the manuscript, study concept and design, interpretation of data, obtaining funding, study supervision, and coordination.
- 1.Paulose-Ram R, Hirsch R, Dillon C, Losonczy K, Cooper M, Ostchega Y (2003) Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf 12:315–326. doi: 10.1002/pds.755 PubMedCrossRefGoogle Scholar
- 6.Lanteri-Minet M, Duru G, Mudge M, Cottrell S (2011) Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: a systematic review. Cephalalgia 31:837–850. doi: 10.1177/0333102411398400 PubMedCrossRefGoogle Scholar
- 7.Steiner TJ, Stovner LJ, Katsarava Z, Lainez JM, Lampl C, Lantéri-Minet M, Rastenyte D, de la Torre ER, Tassorelli C, Barré J, Andrée C (2014) The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 15:31. doi: 10.1186/1129-2377-15-31 PubMedCentralPubMedCrossRefGoogle Scholar
- 16.WHO Collaborating Centre for Drug Statistics Methodology (2011) Use of ATC/DDD, www.whocc.no/use_of_atc_ddd (accessed 11 February 2015)
- 20.20 Bendtsen L, Birk S, Kasch H, Aegidius K, Sørensen PS, Thomsen LL, Poulsen L, Rasmussen MJ, Kruuse C, Jensen R (2012) Danish Headache Society. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition. J Headache Pain 13 Suppl 1: S1–29. doi: 10.1007/s10194-011-0402-9
- 26.Orr SL, Aubé M, Becker WJ, Davenport WJ, Dilli E, Dodick D, Giammarco R, Gladstone J, Leroux E, Pim H, Dickinson G, Christie SN (2015) Canadian Headache Society systematic review and recommendations on the treatment of migraine pain in emergency settings. Cephalalgia 35:271–284. doi: 10.1177/0333102414535997 PubMedCrossRefGoogle Scholar
- 38.Yoon MS, Manack A, Schramm S, Fritsche G, Obermann M, Diener HC, Moebus S, Katsarava Z (2013) Chronic migraine and chronic tension-type headache are associated with concomitant low back pain: results of the German Headache Consortium Study. Pain 154(3):484–492. doi: 10.1016/j.pain.2012.12.010 PubMedCrossRefGoogle Scholar